Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.
Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, Bhambhvani H, Smith K, Johansen JS, Makawita S, Musher B, Mehta A, Hendifar A, Wainberg Z, Sohal D, Fountzilas C, Singhi A, Rajpurkar P, Collisson EA. Nimgaonkar V, et al. Among authors: fountzilas c. Cell Rep Med. 2023 Apr 18;4(4):101013. doi: 10.1016/j.xcrm.2023.101013. Epub 2023 Apr 11. Cell Rep Med. 2023. PMID: 37044094 Free PMC article.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. André T, et al. N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. N Engl J Med. 2020. PMID: 33264544 Free article. Clinical Trial.
A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM, Zonneville J, Naranjo MN, Serio H, Melendy T, Straubinger RM, Gillard B, Foster BA, Rajan P, Attwood K, Chatley S, Iyer R, Fountzilas C, Bakin AV. Alruwaili MM, et al. Among authors: fountzilas c. Cell Rep Med. 2024 Mar 19;5(3):101434. doi: 10.1016/j.xcrm.2024.101434. Epub 2024 Feb 21. Cell Rep Med. 2024. PMID: 38387463 Free PMC article.
Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer.
Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, Attwood K, George M, Rempinski D, Franco-Barraza J, Seshadri M, Parker MD, Cortes Gomez E, Fountzilas C, Cukierman E, Steele NG, Feigin ME. Cornwell AC, et al. Among authors: fountzilas c. Clin Cancer Res. 2023 Sep 15;29(18):3793-3812. doi: 10.1158/1078-0432.CCR-23-0547. Clin Cancer Res. 2023. PMID: 37587561 Free PMC article.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Strickler JH, et al. Among authors: fountzilas c. Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. Lancet Oncol. 2023. PMID: 37142372 Clinical Trial.
Physical Inactivity and Pancreatic Cancer Mortality.
Pratapwar M, Stenzel AE, Joseph JM, Fountzilas C, Etter JL, Mongiovi JM, Cannioto R, Moysich KB. Pratapwar M, et al. Among authors: fountzilas c. J Gastrointest Cancer. 2020 Sep;51(3):1088-1093. doi: 10.1007/s12029-020-00441-9. J Gastrointest Cancer. 2020. PMID: 32524304 Free PMC article.
Immunotherapy in hepatocellular cancer.
Fountzilas C, Evans R, Alaklabi S, Iyer R. Fountzilas C, et al. Adv Cancer Res. 2021;149:295-320. doi: 10.1016/bs.acr.2020.12.002. Epub 2021 Jan 23. Adv Cancer Res. 2021. PMID: 33579426 Review.
57 results